NEW YORK, NY / ACCESSWIRE / April 19, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Meta Platforms, Inc. (NASDAQ:FB)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=26136&wire=1
Lead Plaintiff Deadline: May 9, 2022
Class Period: March 2, 2021 – February 2, 2022
Allegations against FB include that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
Lucid Group, Inc. (NASDAQ:LCID)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/lucid-group-inc-loss-submission-form?prid=26136&wire=1
Lead Plaintiff Deadline: May 31, 2022
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid’s business and operations. Specifically, the Company overstated its production capabilities while concealing that “extraordinary supply chain and logistics challenges” were hampering Lucid’s operations. As a result of the defendants’ wrongful acts and omissions, and the significant decline in the market value of Lucid’s common stock, Lucid investors have suffered significant damages.
AbbVie Inc. (NYSE:ABBV)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=26136&wire=1
Lead Plaintiff Deadline: June 6, 2022
Class Period: April 30, 2021 – August 31, 2021
Allegations against ABBV include that: (1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/698003/SHAREHOLDER-ALERT-FB-LCID-ABBV-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines